On Friday, EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) was -6.33% drop from the session before settling in for the closing price of $11.06. A 52-week range for EYPT has been $3.91 – $13.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 15.65% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -31.19%. With a float of $59.81 million, this company’s outstanding shares have now reached $68.81 million.
In an organization with 165 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 93.29%, operating margin of -287.94%, and the pretax margin is -261.75%.
EyePoint Pharmaceuticals Inc (EYPT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward EyePoint Pharmaceuticals Inc stocks. The insider ownership of EyePoint Pharmaceuticals Inc is 13.08%, while institutional ownership is 98.22%. The most recent insider transaction that took place on May 19 ’25, was worth 29,950. In this transaction Director of this company bought 5,000 shares at a rate of $5.99, taking the stock ownership to the 36,500 shares. Before that another transaction happened on May 16 ’25, when Company’s Director bought 5,000 for $5.81, making the entire transaction worth $29,050. This insider now owns 31,500 shares in total.
EyePoint Pharmaceuticals Inc (EYPT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -31.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.73% during the next five years compared to 15.65% growth over the previous five years of trading.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
You can see what EyePoint Pharmaceuticals Inc (EYPT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.41, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.93 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was better than the volume of 0.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 67.22%.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 82.90%, which indicates a significant increase from 64.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.83 in the past 14 days, which was higher than the 0.58 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.95, while its 200-day Moving Average is $7.87. However, in the short run, EyePoint Pharmaceuticals Inc’s stock first resistance to watch stands at $10.91. Second resistance stands at $11.45. The third major resistance level sits at $11.77. If the price goes on to break the first support level at $10.04, it is likely to go to the next support level at $9.72. The third support level lies at $9.18 if the price breaches the second support level.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
There are 68,811K outstanding shares of the company, which has a market capitalization of 712.89 million. As of now, sales total 43,270 K while income totals -130,870 K. Its latest quarter income was 24,450 K while its last quarter net income were -45,200 K.
